Home > Insider Trading > Filing (0000791908-15-000087)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
791908	Xoma Corp	XOMA	Pharmaceutical Preparations (2834)	942756657

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1210905	D Paul Rubin	C/O Xoma Corporation 2910 Seventh Street Berkeley CA 94710	Sr. Vp Clinical Dev. & Cmo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2015-07-09	4,400	$3.04	126,745	No	4	M	Direct
Common Shares	Disposition	2015-07-09	4,400	$4.55	122,345	No	4	S	Direct
Common Shares	Acquisiton	2015-07-10	29,000	$3.04	151,345	No	4	M	Direct
Common Shares	Disposition	2015-07-10	29,000	$4.55	122,345	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Incentive Share Option (right to buy)	Disposition	2015-07-09	4,400	$3.04	4,400	$3.04
Common Shares	Incentive Share Option (right to buy)	Disposition	2015-07-10	29,000	$3.04	29,000	$3.04

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
61,040		2021-05-31	No	4	M	Direct
32,040		2021-05-31	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares	6,881	Indirect	by 401(k)

Footnotes

This transaction was made pursuant to Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2014.
This transaction was executed in multiple trades, with all trades executing at $4.55. The reporting person hereby undertakes to provide upon request to the SEC staff, the Company or a security holder of the Company full information regarding the number of shares and prices at which the transactions were effected.
This transaction was executed in multiple trades ranging at prices from $4.55 to $4.59. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Company or a security holder of the Company full information regarding the number of shares and prices at which the transactions were effected.
Incentive Stock Option exercisable in conjunction with matching Non-Qualified Stock Option as to (a) 25% of the option shares upon the first anniversary of the date of grant, and (b) the remaining 75% of the option shares in thirty-six (36) equal and consecutive monthly installments beginning one year and one month after the date of grant.